Eddie Gray served as the CEO of Dynavax Technologies from May 1, 2013, until his retirement in August 2019. Under his leadership, the company focused on innovative vaccines, particularly HEPLISAV-B, a hepatitis B vaccine aimed at improving immunization processes. In...

Eddie Gray served as the CEO of Dynavax Technologies from May 1, 2013, until his retirement in August 2019. Under his leadership, the company focused on innovative vaccines, particularly HEPLISAV-B, a hepatitis B vaccine aimed at improving immunization processes. In his final year, Eddie’s total compensation was around $2.42 million, which included retirement benefits worth over $2 million paid out after he left. His management style was centered around aligning executive pay with performance, reflecting the company’s goals. During his tenure, his stock options and incentives heavily depended on achieving corporate objectives, showing a clear commitment to the company's long-term success. Eddie frequently participated in insider trading, with notable transactions reaching up to $5.5 million in a single month in late 2021. This suggests he had significant confidence in Dynavax's future when he was at the helm. His strategic decisions and direction in the field of vaccine development were instrumental during a pivotal time for the company.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

D

Eddie Gray

CEO of Dynavax Technologies

Sector of Economy

Healthcare

CEO of Dynavax Technologies for

12 years 0 months (May 2013 - Present)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Eddie Gray

G

Daniel O'Day

CEO of Gilead Sciences

2023 Compensation

Stock

$16.51M

Salary

$1.74M

Bonus

$0.00

Other

$1.22M

Total Holdings

$103.20M

M

Robert M. Davis

CEO of Merck & Co.

2023 Compensation

Stock

$17.72M

Salary

$1.60M

Bonus

$0.00

Other

$386.15K

Total Holdings

$5.80M

C

Joseph K. Belanoff, M.D.

Founder and CEO of Corcept Therapeutics

2023 Compensation

Stock

$0.00

Salary

$1.10M

Bonus

$1.32M

Other

$22.50K

Total Holdings

$190.37M

A

Richard F. Pops

CEO of Alkermes

2023 Compensation

Stock

$0.00

Salary

$1.18M

Bonus

$1.41M

Other

$16.50K

Total Holdings

$47.82M

L

John L. Higgins

CEO of Ligand Pharmaceuticals

2022 Compensation

Stock

$0.00

Salary

$730.46K

Bonus

$0.00

Other

$0.00

Total Holdings

$48.52M

Holdings

See how much did Eddie Gray make over time.

During his time at Dynavax Technologies, Eddie Gray's investments reflected his confidence in the company he led. He participated in several insider transactions, with notable monthly trades peaking in 2021. In August of that year, he sold shares worth approximately...

During his time at Dynavax Technologies, Eddie Gray's investments reflected his confidence in the company he led. He participated in several insider transactions, with notable monthly trades peaking in 2021. In August of that year, he sold shares worth approximately $5.52 million, indicating a successful phase for the company's stock. Earlier, in late 2019, just after his retirement, he saw considerable fluctuations in his holdings value, starting around $1.20 million and rising steadily as the company's vaccine developments progressed. His stock options granted throughout his tenure often hinged on performance metrics tied to achieving strategic goals. This highlights his belief in the mission of Dynavax and his belief that the company's value would grow over time. His wealth was closely tied to the health of Dynavax, reflecting his commitment to the company's success during his leadership.

Insider Trading

See recent insider trades of Eddie Gray.

DVAX

$42.83K

DVAX at $15.58/share

May 20, 2016

Purchase

Compensation History

See how much did Eddie Gray make over time.

Eddie Gray's compensation package during his time as CEO of Dynavax Technologies varied significantly from year to year. In 2019, his total compensation was approximately $2.42 million, which included a significant severance payment when he retired. In previous years, such as 2017, his total compensation exceeded $3 million, heavily influenced by stock options and performance-based bonuses. Notably, he did not receive any annual cash bonuses in his final year, which can be attributed to his early departure from the company. Over his six-year tenure, Gray's base salary averaged around $600,000, while his total package varied widely based on stock options that were tied to the company’s success in reaching clinical and regulatory milestones for their vaccine products. This pay structure indicates an executive-driven approach aiming to align personal success with company objectives, particularly in the biopharmaceutical sector.

Year

2019

Total Compensation

$2.42M

Salary

$375.80K

Board Justification

Dynavax's compensation philosophy is designed to align executive compensation with performance and the achievement of strategic corporate objectives, ensuring that it is competitive to attract and retain talent.

Bonus

$0.00

Board Justification

Eddie Gray did not receive an annual cash incentive payout for 2019 due to his retirement in August 2019.

Other

$2.05M

Board Justification

This includes a lump-sum cash severance payment of $2,048,000, COBRA payments, and the value of accelerated vesting of outstanding equity awards that were subject to time-based vesting criteria.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2019 as Eddie Gray retired before any performance-based RSUs could vest.

Performance Metrics

Eddie Gray's performance metrics were aligned with corporate goals focused on the commercialization of HEPLISAV-B and the advancement of the company's vaccine development efforts.